A phase I/II, first-in-human trial is assessing its safety when administered alone or in combination with an anti-PD-1 mAb in solid tumors, including NSCLC, expressing B7-H3 (NCT03729596). Here, PDCD1 is linked to non-small cell lung carcinoma.